Список литературы

Поставить закладку

Swerdlow S.H. et al. WHO classiﬁcation of tumours of haematopoietic and lymphoid tissues. International Agency for Research on Cancer, 2008. 439 p.
Swerdlow S.H. et al. WHO classiﬁcation of tumours of haematopoietic and lymphoid tissues. Revised 4th ed. Lyon, France: International Agency for Research in Cancer (IARC) / ed. Swerdlow SH, Campo E, Harris NL, Jaffe ES, Pileri SA, Stein H T.J. 2017. 585 p.
Falini B., Martelli M.P., Tiacci E. BRAF V600E mutation in hairy cell leukemia: From bench to bedside // Blood. American Society of Hematology, 2016. Vol. 128, № 15. P. 1918–1927.
Tadmor T., Polliack A. Epidemiology and environmental risk in hairy cell leukemia // Best Practice and Research: Clinical Haematology. Bailliere Tindall Ltd, 2015. Vol. 28, № 4. P. 175–179.
Аль-Ради Л.С. Волосатоклеточный лейкоз // Российские клинические рекомендации по диагностике и лечению злокачественных лимфопролиферативных заболеваний; под ред. И.В. Поддубной, В.Г. Савченко. 2018. P. 200–213.
Cawley J.C., Burns G.F., Hayhoe F.G. A chronic lymphoproliferative disorder with distinctive features: a distinct variant of hairy-cell leukaemia. // Leuk. Res. 1980. Vol. 4, № 6. P. 547–559.
Аль-Ради Л.С., Пивник А.В. Особенности течения и современная тактика терапии волосатоклеточного лейкоза. // Клиническая онкогематология. 2009. Vol. 2, № 1. P. 111–120.
Matutes E. et al. The immunophenotype of hairy cell leukemia (HCL). Proposal for a scoring system to distinguish HCL from B-cell disorders with hairy or villous lymphocytes. // Leuk. Lymphoma. 1994. Vol. 14 Suppl 1. P. 57–61.
Matutes E., Wotherspoon A., Catovsky D. The variant form of hairy-cell leukaemia. // Best Pract. Res. Clin. Haematol. 2003. Vol. 16, № 1. P. 41–56.
Аль-Ради Л.С. et al. Опыт изучения лимфомы красной пульпы селезенки // Терапевтический архив. 2016. Vol. 88, № 4. P. 53–60.
Troussard X., Cornet E. Hairy cell leukemia 2018: Update on diagnosis, risk-stratiﬁcation, and treatment. // Am. J. Hematol. 2017. Vol. 92, № 12. P. 1382–1390.
Grever M.R. et al. Consensus guidelines for the diagnosis and management of patients with classic hairy cell leukemia. // Blood. 2017. Vol. 129, № 5. P. 553–560.
Robak T. et al. Hairy Cell Leukaemia: ESMO Clinical Practice Guidelines // Ann. Oncol. 2015. Vol. 26, № Suppl. 5. P. v100–v107.
Maitre E., Cornet E., Troussard X. Hairy cell leukemia: 2020 update on diagnosis, risk stratiﬁcation, and treatment // Am. J. Hematol. 2019. Vol. 94, № 12. P. 1413–1422.
Del Giudice I. et al. The diagnostic value of CD123 in B-cell disorders with hairy or villous lymphocytes. // Haematologica. 2004. Vol. 89, № 3. P. 303–308.
Tiacci E. et al. BRAF mutations in hairy-cell leukemia // N. Engl. J. Med. Massachussetts Medical Society, 2011. Vol. 364, № 24. P. 2305–2315.
Arcaini L. et al. The BRAF V600E mutation in hairy cell leukemia and other mature B-cell neoplasms // Blood. 2012. Vol. 119, № 1. P. 188–191.
Демина Е.А. et al. Общие принципы диагностики лимфом // Российские клинические рекомендации по диагностике и лечению злокачественных лимфопролиферативных заболеваний; под ред. И.В. Поддубной, В.Г. Савченко. 2018. P. 9–27.
Kraut E. Infectious complications in hairy cell leukemia // Leuk. Lymphoma. 2011. Vol. 52, № SUPPL. 2. P. 50–52.
Rai K.R. et al. Recombinant alpha-2b-interferon in therapy of previously untreated hairy cell leukemia: long-term follow-up results of study by Cancer and Leukemia Group B. // Leukemia. 1995. Vol. 9, № 7. P. 1116–1120.
Federico M. et al. Long-term results of alpha interferon as initial therapy and splenectomy as consolidation therapy in patients with hairy cell leukemia. Final report from the Italian Cooperative Group for HCL // Ann. Oncol. 1994. Vol. 5, № 8. P. 725–731.
Falini B., Tiacci E. New treatment options in hairy cell leukemia with focus on BRAF inhibitors // Hematol. Oncol. John Wiley and Sons Ltd, 2019. Vol. 37, № S1. P. 30–37.
Dietrich S. et al. BRAF inhibition in hairy cell leukemia with low-dose vemurafenib // Blood. American Society of Hematology, 2016. Vol. 127, № 23. P. 2847–2855.
Andrasiak I., Rybka J., Wrobel T. Response to the Therapy in Hairy Cell Leukemia: Systematic Review and Meta-Analysis. // Clin. Lymphoma. Myeloma Leuk. 2018. Vol. 18, № 6. P. 392-399.e3.
Lauria F., Cencini E., Forconi F. Alternative methods of cladribine administration. // Leuk. Lymphoma. 2011. Vol. 52 Suppl 2. P. 34–37.
Robak T. et al. Cladribine in a weekly versus daily schedule for untreated active hairy cell leukemia: Final report from the Polish Adult Leukemia Group (PALG) of a prospective, randomized, multicenter trial // Blood. 2007. Vol. 109, № 9. P. 3672–3675.
Else M. et al. Long-term follow-up of 233 patients with hairy cell leukaemia, treated initially with pentostatin or cladribine, at a median of 16 years from diagnosis. // Br. J. Haematol. 2009. Vol. 145, № 6. P. 733–740.
Zinzani P.L. et al. Hairy cell leukemia: evaluation of the long-term outcome in 121 patients. // Cancer. 2010. Vol. 116, № 20. P. 4788–4792.
Аль-Ради Л.С. et al. Лечение рецидивов волосатоклеточного лейкоза // Терапевтический архив. 2012. Vol. 7. P. 4–9.
Chihara D. et al. Long-term durable remission by cladribine followed by rituximab in patients with hairy cell leukaemia: update of a phase II trial. // Br. J. Haematol. 2016. Vol. 174, № 5. P. 760–766.
Else M. et al. The role of rituximab in combination with pentostatin or cladribine for the treatment of recurrent/refractory hairy cell leukemia. // Cancer. 2007. Vol. 110, № 10. P. 2240–2247.
Dietrich S. et al. BRAF inhibition in hairy cell leukemia with low-dose vemurafenib. // Blood. 2016. Vol. 127, № 23. P. 2847–2855.
Tiacci E. et al. Targeting mutant BRAF in relapsed or refractory hairy-cell leukemia // N. Engl. J. Med. Massachussetts Medical Society, 2015. Vol. 373, № 18. P. 1733–1747.
Burotto M. et al. Bendamustine and rituximab in relapsed and refractory hairy cell leukemia // Clin. Cancer Res. 2013. Vol. 19, № 22. P. 6313–6321.
Golomb H.M., Hadad L.J. Infectious complications in 127 patients with hairy cell leukemia. // Am. J. Hematol. 1984. Vol. 16, № 4. P. 393–401.
Siegal F.P. et al. Impaired interferon alpha response in hairy cell leukemia is corrected by therapy with 2-chloro-2’-deoxyadenosine: implications for susceptibility to opportunistic infections. // Leukemia. 1994. Vol. 8, № 9. P. 1474–1479.
Адь-Ради Л.С. et al. Туберкулез у больных лимфопролиферативными заболеваниями. // Терапевтический архив. 2014. Vol. 11. P. 42–49.
Saven A. et al. Filgrastim for cladribine-induced neutropenic fever in patients with hairy cell leukemia. // Blood. 1999. Vol. 93, № 8. P. 2471–2477.
Aapro M. et al. Клинические рекомендации по лечению анемии у больных злокачественными новообразованиями. М.: Ассоциация онкологов России, 2014.
Абузарова Г.Р. et al. Обезболивание взрослых и детей при оказании медицинской помощи. Методические рекомендации. ФГБОУ ВО РНИМУ им. Н.И. Пирогова Минздрава России., 2016. 94 p.
Абузарова Г.Р. Лечение болевого синдрома у онкологических больных // Российские клинические рекомендации по диагностике и лечению злокачественных лимфопролиферативных заболеваний; под ред. И.В. Поддубной, В.Г. Савченко. 2018. P. 278– 288.
Paul K.L. Rehabilitation and exercise considerations in hematologic malignancies. // Am. J. Phys. Med. Rehabil. 2011. Vol. 90, № 5 Suppl 1. P. S88-94.
Аль-Ради Л.С. et al. Волосатоклеточный лейкоз и беременность // Терапевтический архив. 2017. Vol. 89, № 7. P. 99–104.
Al Bahar S., Pandita R., Nath S. V. Pregnancy in chronic myeloid leukemia patients treated with alpha interferon. // Int. J. Gynaecol. Obstet. 2004. Vol. 85, № 3. P. 281–282.
Oken M.M. et al. Toxicity and response criteria of the Eastern Cooperative Oncology Group // Am. J. Clin. Oncol. 1982. Vol. 5, № 6. P. 649–655.